Public Profile

Baudax Bio, Inc.

Baudax Bio, Inc., a biopharmaceutical company headquartered in the United States, focuses on developing innovative therapeutics for patients in need. Founded in 2018, Baudax Bio has quickly established itself in the industry, particularly in the areas of pain management and anaesthesia. The company’s flagship product, Exparel, is a unique liposomal formulation of bupivacaine, designed to provide prolonged analgesia with a single administration. This innovative approach sets Baudax Bio apart in a competitive market, addressing the growing demand for effective pain relief solutions. With a commitment to advancing patient care, Baudax Bio has achieved significant milestones, positioning itself as a key player in the biopharmaceutical landscape. The company continues to explore new avenues for growth, aiming to enhance the quality of life for patients worldwide.

DitchCarbon Score

How does Baudax Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

19

Industry Benchmark

Baudax Bio, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.

52%

Baudax Bio, Inc.'s reported carbon emissions

Baudax Bio, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is unclear how the company is addressing its carbon footprint or what commitments it has made towards climate action. In the absence of concrete data, it is essential to monitor the company's future disclosures for any developments in their climate initiatives or emissions reporting.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Baudax Bio, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Baudax Bio, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Baudax Bio, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Was this information valuable to you?

Similar Organizations

Heron Therapeutics, Inc.

US
Health and social work services (85)
Updated about 1 month ago

Cumberland Pharmaceuticals Inc.

US
Chemicals nec
Updated about 1 month ago

Talphera, Inc.

US
Chemicals nec
Updated about 1 month ago

Innocoll Pharmaceuticals Ltd.

IE
Food products nec
Updated 2 months ago
DitchCarbon Score

Mallinckrodt plc

IE
Chemicals nec
Updated 23 days ago

Kowa Pharmaceuticals America, Inc.

US
Chemicals nec
Updated 2 months ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers